SCHEMBL7689491

SCHEMBL7689491

Clc1ccc(OCc2nc3cc(Cl)c(Cl)cc3[nH]2)c(Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.60
NPC1 O15118 4/20 0.60
BRS3 P32247 3/20 0.58
MEN1 O00255 1/20 0.56
USP2 O75604 1/20 0.56
MAPT P10636 1/20 0.56
KMT2A Q03164 1/20 0.56
HSD17B10 Q99714 1/20 0.56
GAA P10253 1/20 0.51
HTT P42858 1/20 0.51
RHEB Q15382 3/20 0.50
TDP1 Q9NUW8 2/20 0.47
POLB P06746 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CACNA1G O43497 1/20 0.46
CACNA1H O95180 1/20 0.46
PDE10A Q9Y233 1/20 0.45
PRKAG1 P54619 1/20 0.45
PRKAA2 P54646 1/20 0.45
PRKAA1 Q13131 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2242937 0.85 RAB9A (0.70) RAB9ANPC1BRS3MEN1USP2
SCHEMBL7684455 0.83 RAB9A (0.68) RAB9ANPC1BRS3MEN1MAPT
SCHEMBL3153713 0.80 RAB9A (0.57) RAB9ANPC1BRS3MEN1USP2
SCHEMBL3152589 0.80 RAB9A (0.57) RAB9ANPC1BRS3MEN1USP2
SCHEMBL3143457 0.78 ALDH1A1 (0.53) RAB9ANPC1BRS3MEN1USP2
SCHEMBL7810958 0.78 BRS3 (0.53) RAB9ANPC1BRS3MEN1USP2
SCHEMBL3148681 0.78 MRGPRX4 (0.52) RAB9ANPC1BRS3MEN1USP2
SCHEMBL7810954 0.78 RAB9A (0.49) RAB9ANPC1BRS3MEN1USP2
SCHEMBL7834239 0.76 MEN1 (0.55) RAB9ANPC1BRS3MEN1USP2
SCHEMBL14765644 0.76 NPC1 (0.50) RAB9ANPC1BRS3MEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020007071-A1 Benzimidzolyl neuropeptide Y receptor antagonists BRITTON THOMAS CHARLES (US) 2002-01-17 US disclosed
US-6255494-B1 SUBSTITUTED BENZIMIDAZOLES USEFUL IN TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH EXCESS OF NEUROPEPTIDE Y (AROUND ARTERIES IN HEART, RESPIRATORY TRACT, GASTROINTESTINAL TRACT AND GENITOURINARY TRACT); ETIOLOGY OF PSYCHIATRIC DISORDERS ELI LILLY AND COMPANY 2001-07-03 US disclosed
EP-0871442-A1 BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 1998-10-21 EP disclosed
WO-1997025041-A1 BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 1997-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020007071-A1 Benzimidzolyl neuropeptide Y receptor antagonists NPY1R, NPY2R, NPY5R RAB9A 3072/4885NPC1 1857/4885BRS3 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.